bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board bioAffinity Technologies, Inc. a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and Scientific Advisory…
UCB Publishes Final Analysis of Fintepla® Open-Label Extension Study in Lennox-Gastaut Syndrome Demonstrating Sustained Seizure Reduction and Improved Quality of Life UCB, a global biopharmaceutical company, announced that the final analysis of its open-label extension (OLE) study evaluating Fintepla® (fenfluramine)…
KalVista Pharmaceuticals to Present New Sebetralstat Data at AAAAI/WAO 2025 Joint Congress KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage pharmaceutical company focused on developing oral therapies for rare diseases, has announced that six abstracts have been accepted for presentation at…
Owkin Announces First Patient Dosed in Phase I Trial of OKN4395 for Solid Tumors Owkin, a leader in AI-driven biotech, has reached a significant milestone in its innovative journey with the dosing of the first patient in the Phase I…
Trinity Life Sciences Launches New Omnichannel Reporting Suite for Enhanced Marketing Insights Trinity Life Sciences, a leader in strategy, insights, and analytics for the life sciences sector, has unveiled an Omnichannel Reporting Suite aimed at improving how life science organizations…
The European Commission (EC) has approved Vabysmo® (faricimab) for treating visual impairment caused by macular edema secondary to retinal vein occlusion (RVO), which includes branch RVO and central RVO. This marks the third approved indication for Vabysmo in the European…
AbbVie Reports Strong Second-Quarter 2024 Financial Performance AbbVie has announced its financial results for the second quarter ending June 30, 2024. “Our business continues to excel, with second-quarter outcomes significantly surpassing our expectations,” stated Robert A. Michael, AbbVie’s Chief Executive…
Today, argenx and Zai Lab announced that China’s National Medical Products Administration (NMPA) approved the Biologics License Application (BLA) for efgartigimod alfa injection (subcutaneous) on July 16, 2024. This 1,000mg (5.6ml)/vial treatment is indicated as an add-on to standard therapy…
Merck, a leader in science and technology, has announced the launch of its first GMP (Good Manufacturing Practices) compliant cell culture media (CCM) manufacturing line in China. The new facility, located at Merck’s Life Science Center in Nantong, represents a…
Bristol Myers Squibb today announced that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line treatment for adult patients with unresectable or advanced hepatocellular carcinoma (HCC) who…
Roche announced today the launch of the first clinically approved, highly-sensitive in-situ hybridisation (ISH) test, the VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries accepting the CE Mark. This test aids pathologists in differentiating between B-cell…
Cranbury Pharmaceuticals (Cranbury), a wholly-owned subsidiary of Tris Pharma, has announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for the first generic version of Emflaza® oral suspension (deflazacort). This medication is…